Remedent, Inc.
REMI · OTC
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,307 | $3,399 | $3,399 | $3,799 |
| - Cash | $43 | $105 | $174 | $78 |
| + Debt | $15 | $0 | $0 | $5 |
| Enterprise Value | $1,279 | $3,294 | $3,225 | $3,727 |
| Revenue | $986 | $864 | $1,408 | $1,030 |
| % Growth | 14.2% | -38.6% | 36.7% | – |
| Gross Profit | $603 | $506 | $1,047 | $579 |
| % Margin | 61.2% | 58.5% | 74.4% | 56.2% |
| EBITDA | -$215 | -$1,443 | -$154 | -$102 |
| % Margin | -21.8% | -167.1% | -10.9% | -9.9% |
| Net Income | -$274 | -$1,495 | -$257 | -$163 |
| % Margin | -27.8% | -173% | -18.3% | -15.8% |
| EPS Diluted | -0.014 | -0.075 | -0.013 | -0.008 |
| % Growth | 81.7% | -479.8% | -57.3% | – |
| Operating Cash Flow | -$131 | -$53 | -$169 | $2 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$131 | -$53 | -$169 | $2 |